Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review
Yazan Migdady, Asiri Ediriwickrema, Ryan Patrick Jackson, Wendy Kadi, Ridhi Gupta, Francisco Socola, Sally Arai, Beth A Martin, Yazan Migdady, Asiri Ediriwickrema, Ryan Patrick Jackson, Wendy Kadi, Ridhi Gupta, Francisco Socola, Sally Arai, Beth A Martin
Abstract
A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations.
A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Figures
Platelet count trends and immunohistochemistry staining. (A) Patient’s platelet count after ITP treatment (including daratumumab) and transfusion needs. (B) CD138 immunohistochemical staining showed increased plasma cells in a spleen section.
Source: PubMed